SEC Form SCHEDULE 13D filed by MaxCyte Inc.
$MXCT
Biotechnology: Commercial Physical & Biological Resarch
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
MAXCYTE, INC. (Name of Issuer) |
equity (Title of Class of Securities) |
57777K106 (CUSIP Number) |
nusayhah ghaboos 30 Coleman street, london, X0, EC2R 5AL 02033275025 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
09/23/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 57777K106 |
| 1 |
Name of reporting person
RIVER GLOBAL INVESTORS LLP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
SC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED KINGDOM
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
5,497,452.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IV |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
equity |
| (b) | Name of Issuer:
MAXCYTE, INC. |
| (c) | Address of Issuer's Principal Executive Offices:
9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE,
MARYLAND
, 20850. |
| Item 2. | Identity and Background |
| (a) | River Global Investors LLP |
| (b) | 30 Coleman Street, London, EC2R 5AL, United Kingdom |
| (c) | River Global Investors LLP - 30 Coleman Street, London, EC2R 5AL, United Kingdom |
| (d) | No |
| (e) | No |
| (f) | United Kingdom |
| Item 3. | Source and Amount of Funds or Other Consideration |
N/A | |
| Item 4. | Purpose of Transaction |
(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 5,497,452
5.1568% |
| (b) | 5,497,452 Shares |
| (c) | 1) River Global Investors LLP
2) Transaction date - 23/09/2025
3) 252,702
4) 20,848 shares priced at USD1.7357 | 143,999 Shares priced at USD1.7390 | 87,755 shares priced at USD 1.5486
5) Conducted on Bloomberg AIM, purchase transaction |
| (d) | N/A |
| (e) | N/A |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
N/A | |
| Item 7. | Material to be Filed as Exhibits. |
N/A |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|